Viewing Study NCT06622005


Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2025-12-26 @ 2:10 AM
Study NCT ID: NCT06622005
Status: RECRUITING
Last Update Posted: 2025-04-16
First Post: 2024-09-30
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Roswell Park Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module